Immix Biopharma (IMMX): Price-to-Projected Revenue Ratio

Immix Biopharma, Inc. (IMMX) relies on external research centers under strict internal supervision. The innovative IMX-110 system integrates clinics into an exclusive therapy network. The forward P/S metric visualizes the current business value relative to revenue, where the value serves as the baseline indicator. Simultaneously, the company is implementing green chemistry principles for the eco-friendly disposal of chemicals in laboratories.

IMMX Immix: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/14/2026

Analytical breakdowns for immixbio.com (IMMX)

- stock price and consensus target price:

Stock Quotes Immix Biopharma|IMMX - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Immix Biopharma, Inc.|IMMX - Business Value

- book value of equity indicators:

Net Assets per Single Share Immix Biopharma|IMMX - Total Stockholders' Equity|Market Cap to Net Assets Ratio immixbio.com|IMMX - Company Balance Sheet Assets

- company total debt and liquidity indicators:

- business earnings and investment ratios data:

IMMX - Net Profit|Expected Profit Immix Biopharma, Inc.|IMMX - Market Cap to Net Income|Projected Price to Earnings Immix Biopharma|IMMX - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Immix Biopharma, Inc.|IMMX - Operating income before deduction of amortization|Earnings per share for the last twelve months Immix Biopharma|IMMX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months immixbio.com|IMMX - Net earnings per share growth this year|Earnings growth forecast for next year Immix Biopharma, Inc.

- revenue and sales details:

IMMX - Company Gross Revenue|Company Future Sales Volume Immix Biopharma|IMMX - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Immix Biopharma, Inc.

Summary company analysis:Immix IMMX

To protect capital from volatility, it is essential for investors to evaluate an asset's value relative to projected revenue. Amidst the fierce race for patient survival in cancer immunotherapy, the future P/S chart for Immix Biopharma, Inc. (IMMX) allows for a comparison of market capitalization against expected sales, identifying the risk of overpayment in the event of clinical trial delays and determining a safe entry point for the portfolio.

Competitor analysis

ImmunityBio - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Holdings IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (Arcus Corp) - Market Cap to Projected Revenue|Zymeworks Inc. (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio tangotx.com (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune Group, Inc.)|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology, Inc.|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech Inc. - Forward Price to Sales|STRO (Sutro Biopharma, Inc.) - Forward P/S Multiple|Forward P/S Multiple minktherapeutics.com|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|ALXO: Future Price to Revenue|Cue Biopharma, Inc. - Forward Price-to-Revenue Multiple|PDS Biotech (PDSB) - Market Cap to Future Revenue Ratio|Sonnet BioTherapeutics Holdings Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio MAIABiotech.com MAIA|Liminatus Pharma LLC (LIMN) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple LAVA Therapeutics|Price-to-Projected Revenue Ratio NextCure Corp|Forward Price-to-Revenue Multiple Leap Tx (LPTX)|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio senseibio.com|Theriva Biologics - Forward Price-to-Revenue Multiple|GRTS: Market Cap to Projected Revenue|KA: Forward Price-to-Revenue Multiple|Forward Price to Sales NEXI (NexImmune Corporation)|TSBX: Forward P/S Multiple|VCNX (vaccinex.com) - Price-to-Projected Revenue Ratio|HARP (Harpoon Therapeutics, Inc.) - Forward P/S Multiple